Gensoric

Gensoric develops and distributes equipment for rapid microbiological and DNA analysis. A rapid diagnosis of the metabolic status and of infections is increasingly recognised as vital for safe and effective patient care. While conventional DNA analysis is performed in specialist centralised laboratories, Gensoric technology is compact and low cost so it can be deployed in individual wards or clinics to support clinical decision-making and personalised drug treatment for individual patients.

Gensoric develops and distributes equipment for rapid microbiological and DNA analysis. Gensoric´s techniques and equipment can provide clinics and industrial laboratories with a faster, more reliable and less costly DNA and biochemical markers analysis method than previously available. Whilst conventional DNA Analysis is performed in specialised laboratories, the compact and low cost Gensoric technology can be deployed at individual clinic or wards, providing rapid and detailed monitoring to support clinical decision-making and personalized drug treatment for individual patients. A rapid diagnosis of the metabolic status and of infections is increasingly recognised as vital for a safe and effective patient care.

Gensoric has developed several devices with different aims:

  • A tool capable of simultaneous analysis of DNA along with 16 additional clinical parameters. This instrument is currently being used to identify and characterize causes of infection in order to guide the selection of appropriate therapy in a clinical setting. This device enables the analysis to be carried out directly on the patient or at point-of-care, delivering a rapid, precise diagnosis of disease or infection.
  • A tool enabling the electrochemical analysis of biological components and DNA for industrial markets; including the analysis of genetically modified food and water quality.
  • A recently launched 3rd device based on the electro-synthesis of pure, chiral pharmaceutical agents, is being evaluated in the framework of a pilot project with Oxford University and by several specialised chemical companies.


The Gensoric technology is protected by patents.

The market for DNA analysis, particularly for in-vitro-diagnostics and corresponding molecular test kits, is highly competitive. The future growth of this market is fundamentally driven by the trend towards decentralized analytic and diagnostic services in hospitals and the call for integrated and easily operated systems. Gensoric’s products meet clear market needs and have unique features which distinguish them from conventional DNA analysis systems.